Mouse defensive behaviors: Pharmacological and behavioral assays for anxiety and panic

Neuroscience and Biobehavioral Reviews

Volumn 25, Issue 3, 2001, Pages 205-218

  Blanchard, D Caroline ^a,b   Griebel, Guy ^c   Blanchard, Robert J ^d  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c SANOFI   (France)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

Behavioral assays; Defense; Defensive behavior; Flight; Mouse models; Panic; Panicogenic; Panicolytics

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ALPRAZOLAM; AMITRIPTYLINE; ANTIPANIC AGENT; BROFAROMINE; BUSPIRONE; CAFFEINE; CLOBAZAM; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE; COCAINE; DESIPRAMINE; DEXFENFLURAMINE; DIAZEPAM; FLESINOXAN; FLUMAZENIL; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRAGASTRIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; YOHIMBINE;

ALERTNESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR; CLINICAL FEATURE; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FLIGHT; FREEZING; GENETIC MANIPULATION; MALE; MENTAL DISEASE; MOUSE; NONHUMAN; PANIC; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SOCIAL ENVIRONMENT; SPECIES DIFFERENCE; STIMULUS; STIMULUS RESPONSE; VOCALIZATION;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; MICE; PANIC;

EID: 0034989828     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(01)00009-4     Document Type: Article

References (107)

1. A double-blind, placebo-controlled study of a CCKB receptor antagonist, CI-988, in patients with generalized anxiety disorder
2. A psychobiological model for panic: Including models for the mechanisms involved in the regulation of mood and anxiety and implications for behavioural and pharmacological therapies
3. Efficacy of benzodiazepines in panic disorder and agoraphobia
4. A comparison of amitriptyline and a fluphenazine/nortriptyline preparation in anxiety-depressive states
5. Stimulus and environmental control of defensive behaviors
6. Cocaine potentiates defensive behaviors related to fear and anxiety
7. Risk assessment and animal models of anxiety
8. Sex differences in the incidence and sonographic characteristics of antipredator ultrasonic cries in the laboratory rat (R. norvegicus)
9. Twenty-two kHz alarm cries to presentation of a predator, by laboratory rats living in visible burrow systems
10. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries
11. Defensive behaviors in wild and laboratory (swiss) mice: The mouse defense test battery
12. Cocaine produces panic-like flight responses in mice in the mouse defense test battery
13. Antipredator behavior of Swiss-Webster mice in a visible burrow system
14. Yohimbine potentiates active defensive responses to threatening stimuli in SwissWebster mice
15. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: Clinical issues and future directions
16. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder
17. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks
18. Reversible inhibitors of monoamine oxidase A in anxiety disorders
19. Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder
20. Serotonin function in anxiety II: Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects
21. Panic and hypertension associated with a single dose of buspirone
22. Chronic antidepressant and clonidine treatment effects on conflict behavior in the rat
23. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice
24. Behavioural endocrinology and reproduction: An evolutionary perspective
25. Absence of central effects in man of the benzodiazepine antagonist Ro 151788
26. An outpatient evaluation of phenelzine and imipramine
27. Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs
28. Effect of predator exposure upon early pregnancy in mice
29. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: Preliminary findings
30. 5-HT and mechanisms of defense
31. 5-HT receptor mechanisms in human anxiety
32. Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin
33. Review of current treatment in panic disorder
34. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study
35. Chronic anxiolytic treatment effects on conflict behavior in the rat
36. Some quantitative properties of anxiety
37. Effects of acute and chronic antipanic drug administration on conflict behavior in the rat
38. Effects of acute and chronic imipramine administration on conflict behavior in the rat: A potential 'animal model' for the study of panic disorder?
39. The effect of buspirone on panic disorder: A case report
40. Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety
41. The elevated T-maze as an experimental model of anxiety
42. Role of the amygdala and periaqueductal gray in anxiety and panic
43. Opposed regulation by dorsal raphe nucleus 5-HT pathways of two types of fear in the elevated T-maze
44. Predator-elicited flight responses in SwissWebster mice: An experimental model of panic attacks
45. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: Correlation with changes in monoamine-oxidase activity and monoamine levels
46. A comparative study of the effects of selective and non selective 5 HT2 receptor subtype antagonists in rat and mouse models of anxiety
47. Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and antipanic drugs
48. Characterization of the behavioral profile of the non peptide CRF receptor antagonist CP154,526 in anxiety models in rodents - Comparison with diazepam and buspirone
49. Genetic differences in the mouse defense test battery
50. Flumazenil-precipitated panic and dysphoria in patients dependent on benzodiazepines: A possible aid to abstinence
51. The effects of the benzodiazepine antagonist Ro 151788 on psychophysiological performance and subjective measures in normal subjects
52. Effects of serotonin receptor antagonists on PAG stimulation induced aversion: Different contributions of 5-HT1, 5-HT2 and 5-HT3 receptors
53. Opposite control mediated by central 5-HT1A and non-5-HT1A (5 HT1B or 5-HT1C) receptors on periaqueductal gray aversion
54. Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats
55. The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats
56. Antiaversive effects of 5-HT(2C) receptor agonists and fluoxetine in a model of panic-like anxiety in rats
57. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: Elements of face and predictive validity
58. 5-HT-sub(1C) receptors in the serotonergic control of periaqueductal gray induced aversion in rats
59. CCK4-induced panic in healthy subjects I: Psychological and cardiovascular effects
60. Panic disorder: Pathophysiology and drug treatment
61. The influence of panic attacks on response to phenelzine and amitriptyline in depressed outpatients
62. NE and 5-HT receptors involved in elicing paniclike responses following iv infusions of yohimbine and fenfluramine
63. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
64. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder
65. Panic and depression: A worldwide primary care perspective
66. Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of panic disorder: Brief review
67. Differential effects of d- and l-amphetamine on mouse-killing behavior in rats
68. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti panic drugs
69. Role of 5-HT2A and 5-HT2A receptor subtypes in the two types of fear generated by the elevated T-maze
70. Panic attacks, buspirone, and serotonin function
71. Diazepam and propranolol in panic disorder and agoraphobia
72. Panic attacks: A neurochemical overview of models and mechanisms
73. Placebo-controlled trial of the CCKB antagonist, CI-988, in panic disorder
74. Play fighting of rats in comparative perspective: A schema for neurobehavioral analyses
75. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
76. Opposite effects of pentylenetetrazol on self-defensive and submissive postures in the rat
77. Serotonergic anxiolytics in the treatment of panic disorder: A controlled study with buspirone
78. Resistance of California ground squirrels (Spermophilus beecheyi) to the venom of the northern Pacific rattlesnake (Crotalus viridis oreganus): A study of adaptive variation
79. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders
80. Animal models of 'anxiety': Where next?
81. Changes in predatory and intraspecific aggressiveness of the male rat during food deprivation
82. Results of stimulation and destruction of posterior hippocampus in cases with violent, aggressive and restless behaviors
83. Panic attack precipitated by fluoxetine
84. Escape and approach induced by brain stimulation: A parametric analysis
85. Intrinsic activity of the benzodiazepine antagonist Ro 151788 in man: An electrophysiological investigation
86. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test
87. Buspirone in the treatment of panic disorder: A controlled pilot comparison with clorazepate
88. GABA receptors in the region of the dorsomedial hypothalamus of rats regulate anxiety in the elevated plus-maze test I: Behavioral measures
89. Effects of treatment with imipramine and clonazepam on an animal model of panic disorder
90. Defense reaction elicited by injection of GABA antagonists and synthesis inhibitors into the posterior hypothalamus in rats
91. Biological hierarchies and the concept of homology
92. Fenfluramine provocation of anxiety in patients with panic disorder
93. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety
94. Moclobemide for anxiety disorders: A focus on moclobemide for panic disorder
95. Vigilance and spatial cohesion among blue monkeys
96. A doubleblind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder
97. Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder
98. The elevated T-maze: A new animal model of anxiety and memory
99. Developments in the drug treatment of panic disorder: What is the place of the selective serotonin reuptake inhibitors?
100. Flesinoxan, a selective 5-HT1A agonist, in the treatment of panic disorder
101. Evidence for rodent-common and species-typical limb and digit use in eating, derived from a comparative analysis of ten rodent species